hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The lack of HAND1 detection in the developing embryo leads to many of the structural defects that causes heart disease and facial deformities while the dosage of HAND1 relates to the severity of these maladies. HAND factors function in the formation of the right ventricle, left ventricle, aortic arch arteries, epicardium, and endocardium implicating them as mediators of congenital heart disease. In addition, HAND1 is uniquely expressed in trophoblasts and is essential for early trophoblast differentiation.
In terms of race, the half-life is 25% higher in Asian patients compared to Caucasians. For the extended-release formulation, it has a half-life of 10.7-15.8 hours in healthy adult patients. Alprazolam has a volume of distribution following oral administration of 0.8-1.3L/kg. Its protein binding in plasma is 80% (mainly albumin bound) and capable of crossing the blood-brain barrier. It is metabolized to less effective metabolites by various CYP450 enzymes including CYP3A4, CYP3A5, CYP3A7, and CYP2C9. The majority of alprazolam metabolism is mediated by hydroxylation via CYP3As. 4-hydroxyalprazolam has 20% the binding affinity of the parent drug, alpha-hydroxyalprazolam has 66% the affinity, and the benzophenone metabolite has <1% the affinity. The drugs are mainly excreted in urine as unchanged Alprazolam. <10% of the dose is eliminated as alpha-hydroxy-alprazolam and 4-hydroxy-alprazolam.
All the secondary ions generated in SIMS analysis originate from the topmost monolayers of the bombarded solid. This means that all different modes of SIMS analysis are basically surface analysis; secondary-ion emissions—atomic as well as molecular—reflect the chemical composition of the near-surface region of the bombarded solid. However, the intention of different SIMS analyses may be quite different. This depends on the erosion rate of the surface, which is controlled by the dose of the primary ions. It may be bulk analysis (dynamic SIMS) or a true analysis of originally uppermost monolayer of a condensed phase (static SIMS).
=== Sealing of the Guwahati factory === In 2022, the Mumbai Crime Branch closed down the company's Guwahati facility after discovering that a Pan masala product produced by the company in Guwahati was found in the possession of a dealer in Solapur (Maharashtra), where the manufacturing, selling, and storage of Pan masala are prohibited. However, within two weeks, the factory was de-sealed following a Guwahati High Court order.
In the early 16th century, northern India—then mainly under Muslim rulers—fell again to the superior mobility and firepower of a new generation of Central Asian warriors. The resulting Mughal Empire did not stamp out the local societies it came to rule. Instead, it balanced and pacified them through new administrative practices and diverse and inclusive ruling elites. This led to more systematic, centralised, and uniform rule. By departing from tribal bonds and exclusive Islamic identity, particularly under Akbar, the Mughals united their vast empire through personal loyalty to a near-divine emperor, expressed through a shared Persianised culture. The Mughal state derived most revenue from agriculture. Its economic policies mandated tax payments in a well-regulated silver currency, and integrated peasants and artisans into larger markets. The relative peace the empire maintained across much of the 17th century helped drive India's economic expansion. Mughal ruling classes fostered extensive patronage of the arts, including painting, literary forms, textiles, and architecture. Newly coherent social groups in northern and western India, such as the Marathas, the Rajputs, and the Sikhs, gained governing ambitions during Mughal rule. Through collaboration or adversity, the Mughals gave them recognition and military experience. Expanding commerce gave rise to new Indian commercial and political elites along the coasts of southern and eastern India.
Sources: en.wikipedia.org
== Prognosis == The availability of treatments that modify the course of multiple sclerosis beginning in the 1990s, known as disease-modifying therapies (DMTs), has improved prognosis. These treatments can reduce relapses and slow progression, but there is no cure. Before the advent of these medications, it took around 15 years before relapsing-remitting MS progressed to secondary progressive MS (which has associated mobility issues). With these medications, the progression is slower to 40 years. The prognosis of MS depends on the subtype of the disease, and there is considerable individual variation in the progression of the disease. In relapsing MS, the most common subtype, a 2016 cohort study found that after a median of 16.8 years from onset, one in ten needed a walking aid, and almost two in ten transitioned to secondary progressive MS, a form characterized by more progressive decline. With treatments available in the 2020s, relapses can be eliminated or substantially reduced. However, "silent progression" of the disease still occurs. In addition to secondary progressive MS (SPMS), a small proportion of people with MS (10–15%) experience progressive decline from the onset, known as primary progressive MS (PPMS). Most treatments have been approved for use in relapsing MS; there are fewer treatments with lower efficacy for progressive forms of MS. The prognosis for progressive MS is worse, with faster accumulation of disability, though with considerable individual variation.
=== Efficiency === The high efficiency is the most important feature of the method. In a multi step (n) synthesis using equal number of BBs (k) in every step the number of components in a forming combinatorial library (N) is: N=kn This means that the number of components increases exponentially with the number steps (cycles) while the number of the required couplings increases only linearly. If a different number of building BBs are used in the cycles (k1, k2, k3....kn) the number of the formed components is: N=k1.k2.k3...kn. This feature of the procedure offers the possibility to synthesize a practically unlimited number of compounds. For example, if 1000 BBs are used in four cycles 1 trillion compounds are expected to form. The number of needed couplings is only 4000!
Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including sertraline. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. The DSM-5 noted in 2013 that serotonin reuptake inhibitor-induced sexual dysfunction may persist after the agent is discontinued. The UK's Medicines and Healthcare products Regulatory Agency received its first report of a sexual dysfunction persisting after an SSRI was stopped — involving fluoxetine — in 1991, and sertraline has been among the SSRIs most frequently implicated in subsequent reports. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction at approximately 0.46% of patients treated with serotonergic antidepressants, including SSRIs, though the actual prevalence remains uncertain and the condition is likely underreported. A 2023 systematic review found that nearly every SSRI currently marketed has been associated with reports of PSSD, with escitalopram, citalopram, paroxetine, sertraline, and fluoxetine accounting for the majority of reported cases.
== Organization == IMA Life is one of the four main divisions of the IMA group. IMA has 4 divisions dedicated to business areas in the main packaging and processing sectors: IMA Flavour (Tea & Coffee Packaging Solutions), IMA Active Division (Solid Dose Solutions), IMA Life (Aseptic Processing & Freeze Drying Solutions) and IMA Safe (Packaging Solutions). The last three business areas also manage companies operating in their respective sectors. The parent company, IMA is a multinational Italian company based in Bologna, Italy with a consolidated turnover of 505.8 million Euros.
Sources: en.wikipedia.org
Naegleria fowleri, also known as the brain-eating amoeba or brain-eating amoeboid, is a species of the genus Naegleria. It belongs to the phylum Percolozoa and is classified as an amoeboflagellate excavate, an organism capable of behaving as both an amoeba and a flagellate. This free-living microorganism primarily feeds on bacteria, but can become pathogenic in humans, causing an extremely rare, sudden, severe, and almost always fatal brain infection known as primary amoebic meningoencephalitis (PAM), also known as naegleriasis. It is typically found in warm freshwater bodies such as lakes, rivers, hot springs, warm water discharge from industrial or power plants, geothermal well water, poorly maintained or minimally chlorinated swimming pools with residual chlorine levels under 0.5 g/m3, water heaters, soil, and pipes connected to tap water. It can exist in either an amoeboid or temporary flagellate stage.
=== mzXML === mzXML is an XML-based common file format for proteomics mass spectrometric data, developed at the Seattle Proteome Center/Institute for Systems Biology while the HUPO-PSI was trying to specify the standardized mzData format. As of 2026, it is still used by members of the proteomics community.
Agriculture's role in developed countries has drastically changed in the last century due to many factors, including refrigeration. Statistics from the 2007 census gives information on the large concentration of agricultural sales coming from a small portion of the existing farms in the United States today. This is a partial result of the market created for the frozen meat trade by the first successful shipment of frozen sheep carcasses coming from New Zealand in the 1880s. As the market continued to grow, regulations on food processing and quality began to be enforced. Eventually, electricity was introduced into rural homes in the United States, which allowed refrigeration technology to continue to expand on the farm, increasing output per person. Today, refrigeration's use on the farm reduces humidity levels, avoids spoiling due to bacterial growth, and assists in preservation.
== Colombia == In the late 1980s, major narcotics trafficking and terrorist problems within the region covered by the Southern Command (USSOUTHCOM) worsened. USSOUTHCOM was (and remains) responsible for all of South America, Central America, and the Caribbean (CARIBCOM). The 7th Special Forces Group deployed detachments, trainers and advisers in conjunction with teams from the 1st Psychological Operations Battalion to assist Host Nation (HN) forces. During the late 1990s, 7 SFG(A) also deployed to Colombia and trained three Counter Narcotics Battalions and assisted in the establishment of a Brigade Headquarters. These were the first units of their kind in Colombia and each is known as "Batallón Contra Narcotraficantes" or BACNA. These elements continue to be very successful against the narcotics industry which thrives in Colombia. U.S. Army Special Forces detachments still rotate among various locations within Colombia, training HN units in counter-guerrilla and counter-narcotics roles, and SF detachments routinely deploy to other countries within the USSOUTHCOM area of responsibility.
== Cause == The cause of lipedema is still unknown. There are various hypotheses about its pathophysiology, including altered adipogenesis, microangiopathy, and damage to the lymphatic system disturbing its microcirculation. Lipedema has been described in familial clusters, suggesting a genetic component. It often appears around times of hormonal change such as puberty, pregnancy, and menopause, suggesting a potential hormonal component. Having obesity does not cause lipedema, but more than half of people with the condition have a BMI higher than 35.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.